Evidence review · from the 250-topic plan
The lab panel: bloodwork before and during GLP-1 therapy, sensibly
No law requires labs before a GLP-1 prescription — and thoughtful care usually wants some anyway, for two reasons that compound: a baseline documents the comorbidities that justify therapy (the A1c, lipids, and metabolic markers that power insurance appeals) and follow-ups document the wins (the improving numbers that make maintenance conversations and coverage cases). The commonly reasonable baseline set to discuss with your prescriber: glucose/A1c, a lipid panel, a comprehensive metabolic panel (liver and kidney function included), blood pressure on record, and thyroid testing where symptoms or history point. During therapy: periodic re-checks of what was abnormal, plus situation-triggered adds (ferritin and TSH for heavy shedding; renal tracking where the kidney file applies). What's oversold: boutique mega-panels and micronutrient fishing expeditions without indications. How telehealth handles it, what it costs, and the documentation dividend — below. Ordering decisions belong to clinicians; this file is the conversation map.
Why labs, when nothing requires them
The class's safety profile doesn't hang on pre-treatment bloodwork — trials enrolled on clinical criteria, and the one boxed contraindication screens by history, not by a lab (routine calcitonin testing isn't recommended). So the case for labs is strategic, not gatekeeping: a documented baseline turns “I feel better” into “A1c fell from prediabetic to normal, triglycerides dropped by a third” — the sentences that win prior-auth appeals, justify maintenance coverage, and give any future specialist a starting map. Baselines are also the only honest way to attribute change: without the before, every after is a story.
The sensible baseline set — to discuss, not to demand
Glucose and A1c: the metabolic headline — prediabetes documented at baseline is both an appeal lever and, per the three-year prevention data, a number this therapy visibly moves. Lipid panel: cholesterol and triglycerides track with weight and respond with it — a second win-documenting line. Comprehensive metabolic panel: liver enzymes (fatty-liver improvement is one of the class's quiet stories) and kidney function (baseline creatinine matters for anyone in FLOW's neighborhood, and for the rare dehydration-stress scenarios the protocol's hydration rules exist to prevent). Blood pressure on record: free, and among the most reliably improving numbers. Thyroid (TSH) where indicated: symptoms, history, or levothyroxine use — not as routine screening. The list's shape is deliberate: standard panels any clinician recognizes, each earning its draw with a specific job.
During therapy — re-check what was abnormal, add what symptoms earn
The cadence logic: anything abnormal at baseline gets a re-check on a clinician-set interval (A1c's natural rhythm is roughly quarterly; lipids often annually-ish unless treatment decisions hang on them); anything normal at baseline mostly stays untested unless symptoms vote. The situation-triggered adds this library has already flagged: ferritin and TSH when shedding is heavy or prolonged; renal function tracking for CKD-adjacent charts; glucose vigilance where insulin or sulfonylureas share the regimen (their doses, not the GLP-1's, usually need the adjusting). And one honest deletion: routine “drug-level” or safety-surveillance labs for the GLP-1 itself aren't a thing — the class doesn't require them, and programs selling mandatory proprietary panels are selling.
The oversold shelf
Boutique testing culture loves a captive audience, so name the patterns: mega-panels (dozens of biomarkers, impressive PDFs, no decision any result would change); micronutrient fishing without symptoms or indication (and remember biotin's lab-interference problem runs the other direction — supplements distorting tests); hormone-panel upsells framed as weight-loss prerequisites; and subscription lab bundles whose recurring revenue is the actual indication. The filter is one question: “what decision changes based on this result?” — a real answer earns the draw; silence is the answer.
How telehealth handles labs — three lanes and a cost note
Lane one: program-ordered — some programs order through national lab chains (walk in, results flow back). Lane two: bring-your-own — recent results from your PCP upload into intake; the cheapest lane when a physical already happened. Lane three: the specialist pairing — per the hybrid model, an obesity-medicine or primary-care visit that orders labs often bills as covered E&M care even when the drugs are cash-pay, making the oversight layer the cheapest lab lane of all. Cash prices for the standard panels above run modest at direct-pay labs; HSA/FSA applies; and every result belongs in the packet, where it compounds. A program's lab posture is also a quiet tell: flexible-and-sensible signals medicine; mandatory-proprietary-panel signals retail. Care that reads your numbers ↗
FAQ
Do I need blood tests before starting a GLP-1?
Not by requirement — the boxed contraindication screens by history, not labs — but a baseline (A1c, lipids, CMP, blood pressure; TSH where indicated) documents comorbidities for appeals and makes improvement measurable.
What labs should be repeated during therapy?
Re-check what was abnormal on clinician-set intervals; add ferritin/TSH for heavy shedding, renal tracking for kidney-adjacent charts, and glucose vigilance when insulin or sulfonylureas share the regimen.
Are big boutique lab panels worth it?
Rarely — apply the one-question filter: what decision changes based on this result? Panels without answers are products, not medicine.
How do labs work with telehealth GLP-1 programs?
Program-ordered, bring-your-own from your PCP, or via a specialist visit that often bills as covered E&M care — the last being the cheapest oversight-plus-labs lane.
Sources
- Label screening guidance (history-based MTC/MEN2; no routine calcitonin).
- Standard metabolic-panel practice; trial-documented marker improvements.
- Companion files: appeal anatomy, interactions, shedding, kidney, second opinion.